Central America (Costa Rica, Panama, Guatemala and Dominican Republic) Acute Myeloid Leukemia Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Country Level
  • 350 Pages
  • No of Tables: 72
  • No of Figures: 47

Central America (Costa Rica, Panama, Guatemala and Dominican Republic) Acute Myeloid Leukemia Drugs Market, By Sub-type (M0 (Undifferentiated Acute Myelobastic Leukemia), M1 (Acute Myeloblastic Leukemia with Minimal Maturation), M2 (Acute Myeloblastic Leukemia with Maturation), M3 (Acute Promyelocytic Leukemia (APL)), M4 (Acute Myelomonocytic Leukemia), M5 (Acute Monocytic Leukemia), M6 (Acute Erythroid Leukemia) & M7 (Acute Megakaryoblastic Leukemia)), Drugs (Chemotherapy, Targeted Therapy & Immunotherapy), Drug Type (Branded & Generics), Route of Administration (Oral, Parenteral and Others), Population Type (Geriatric, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Ambulatory Centers & Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) Industry Trends and Forecast to 2029.

 Market Analysis and Insights

Acute myeloid leukemia (AML) is a type of blood cancer that affects the bone marrow. In adults, it is the most frequent kind of acute leukemia. If left untreated, this type of cancer usually worsens swiftly. AML, also known as acute myelogenous leukemia or acute nonlymphocytic leukemia, is a kind of leukemia that affects the blood cells.

Blood stem cells (immature cells) are produced in the bone marrow and over time they become mature. A blood stem cell can differentiate into a myeloid or lymphoid stem cell. A white blood cell develops from a lymphoid stem cell. A mature blood cell from a myeloid stem cell is one of three types that are red blood cells, granulocytes, and platelets.

Data Bridge Market Research analyses that the Central America (Costa Rica, Panama, Guatemala and Dominican Republic) acute myeloid leukemia drugs market will grow at a CAGR of 5.5% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

By Sub-type (M0 (Undifferentiated Acute Myelobastic Leukemia), M1 (Acute Myeloblastic Leukemia with Minimal Maturation), M2 (Acute Myeloblastic Leukemia with Maturation), M3 (Acute Promyelocytic Leukemia (APL)), M4 (Acute Myelomonocytic Leukemia), M5 (Acute Monocytic Leukemia), M6 (Acute Erythroid Leukemia) & M7 (Acute Megakaryoblastic Leukemia)), Drugs (Chemotherapy, Targeted Therapy & Immunotherapy), Drug Type (Branded & Generics), Route of Administration (Oral, Parenteral and Others), Population Type (Geriatric, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Ambulatory Centers & Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy & Others)

Countries Covered

Costa Rica, Panama, Dominican Republic, Guatemala, and Rest of Central America

Market Players Covered

Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF Merck & Co., Inc.) (U.S.), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) (U.S.), AstraZeneca (U.K.), Viatris Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Fresenius Kabi AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel) and Sun Pharmaceutical Industries Ltd. (India)

Acute Myeloid Leukemia Drugs Market Dynamics

Drivers

Age is a major factor in cancer progression since age is an essential parameter that effects the fundamental biological mechanisms. Acute myeloid leukemia (AML) is an acute hematological malignancy that affects mostly older people. The unfavorable aspects of AML in the elderly, as well as the frailties and comorbidities associated with it, are very common in this population, which makes treatment an especially challenging task. Thus, the growing pace of the geriatric population is demonstrating the escalation in a number of cancer treatments across the globe. Consequently, the demand for cancer treatment is anticipated to upsurge. Owning to this, it is estimated that the growing geriatric population is expected to be a major driving factor for the growth of the market

  • Rising investment in research and development

As the companies are constantly engaged in research and developmental activities, the process of drug discovery and development would bring a new compound with proven therapeutic effect to the market. It would aid in more collaborations and partnerships with market players. This signifies an increase in research and development investments to discover and develop new drug treatments, which is expected to boost the market growth

  • Rising clinical trials and product approval

Oncological trials are increasing in Central America (Costa Rica, Panama, Guatemala and Dominican Republic) over the years which is expected to drive the growth of the acute myeloid leukemia drugs market.

Furthermore, advancement in medical technology and rising incidence of acute myeloid leukemia are the factors that will expand the acute myeloid leukemia drugs market.

Opportunities

  • Rise in healthcare expenditure

Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. The above are expected to create lucrative opportunities for the Central America (Costa Rica, Panama, Guatemala, and Dominican Republic) acute myeloid leukemia drugs market.

Also, the launch of effective drugs and continuous clinical trials will provide beneficial opportunities for the acute myeloid leukemia drugs market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate of acute myeloid leukemia drugs market in future.

Restraints/Challenges

However, adverse effects associated with acute myeloid leukemia drugs and high cost of cancer medicines will impede the growth rate of acute myeloid leukemia drugs market. Additionally, lack of skilled professionals will further challenge the market in the forecast period mentioned above.

This acute myeloid leukemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute myeloid leukemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to a study, acute myeloid leukemia incidence rate in developing countries generally ranged from 3.0 to 4.0 cases per 100,000 person-years in the adult population.

The median age at diagnosis is about 70 years. Most patients with AML present with signs and symptoms arising from bone marrow failure and organ infiltration by leukaemic cells.

Acute myeloid leukemia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Acute Myeloid Leukemia Drugs Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in acute myeloid leukemia drugs adherence during the pandemic.

Recent Development

  • In June 2021, Bristol Myers Squibb received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post-marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Central America, thereby increasing the market growth

Central America (Costa Rica, Panama, Guatemala and Dominican Republic) Acute Myeloid Leukemia Drugs Market Scope and Market Size

Central America (Costa Rica, Panama, Guatemala and Dominican Republic) acute myeloid leukemia drugs market is segmented into seven notable segments which are by sub-type, drugs, drug type, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Sub--Type

  • M0 (Undifferentiated Acute Myelobastic Leukemia)
  • M1 (Acute Myeloblastic Leukemia with Minimal Maturation)
  • M2 (Acute Myeloblastic Leukemia with Maturation)
  • M3 (Acute Promyelocytic Leukemia (APL)
  • M4 (Acute Myelomonocytic Leukemia)
  • M5 (Acute Monocytic Leukemia)
  • M6 (Acute Erythroid Leukemia)
  • M7 (Acute Megakaryoblastic Leukemia)

On the basis of sub-type, the acute myeloid leukemia drugs market is segmented into M0 (Undifferentiated Acute Myelobastic Leukemia), M1 (Acute Myeloblastic Leukemia with Minimal Maturation), M2 (Acute Myeloblastic Leukemia with Maturation), M3 (Acute Promyelocytic Leukemia (APL)), M4 (Acute Myelomonocytic Leukemia), M5 (Acute Monocytic Leukemia), M6 (Acute Erythroid Leukemia) and M7 (Acute Megakaryoblastic Leukemia).

Drugs

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

On the basis of drugs, the acute myeloid leukemia drugs market is segmented into chemotherapy, targeted therapy and immunotherapy.

Drug Type

  • Branded
  • Generics

On the basis of drug type, the acute myeloid leukemia drugs market is segmented into branded and generics.

Route of Administration

  • Parenteral
  • Oral
  • Others

On the basis of route of administration, the acute myeloid leukemia drugs market is segmented into parenteral, oral and others.

Population Type

  • Geriatric
  • Adults
  • Pediatric

On the basis of population type, the acute myeloid leukemia drugs market is segmented into geriatric, adults and pediatric.

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Centers
  • Others

On the basis of end user, the acute myeloid leukemia drugs market is segmented into hospitals, specialty clinics, ambulatory centres and others.

Distribution Channel

  • Direct Tender
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the acute myeloid leukemia drugs market is segmented into direct tender, hospitals pharmacy, retail pharmacy, online pharmacy, and others.

Pipeline Analysis

The pipeline analysis of acute myeloid leukemia drugs includes various pipeline drugs such as cytarabine, decitabine, AZD5991 and BI836858. AstraZeneca, AbbVie Inc., Boehringer Ingelheim International GmbH and others are the involved in the development of potential drugs for the improvement of treatment of acute myeloid leukemia.

Acute Myeloid Leukemia Drugs Market Country Analysis/Insights    

The acute myeloid leukemia drugs market is analysed and market size insights and trends are provided by country, sub-type, drugs, drug type route of administration, population type, end user and distribution channel as referenced above.

The countries covered in the Central America (Costa Rica, Panama, Guatemala and Dominican Republic) acute myeloid leukemia drugs market report are Costa Rica, Panama, Dominican Republic, Guatemala, and rest of Central America.

Costa Rica dominates the Central America (Costa Rica, Panama, Guatemala and Dominican Republic) acute myeloid leukemia drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing prevalence of cancer. The quality of healthcare in the country is further enhancing the market growth.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Acute Myeloid Leukemia Drugs Market Share Analysis

The acute myeloid leukemia drugs market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on acute myeloid leukemia drugs market.

Some of the major players operating in the acute myeloid leukemia drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF Merck & Co., Inc.), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), AstraZeneca, Viatris Inc., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report. 


SKU-

TABLE 1 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

TABLE 2 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 3 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 4 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 5 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 6 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 7 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 8 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 9 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 10 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 11 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 12 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 13 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 14 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 15 CENTRAL AMERICA (COSTA RICA, PANAMA, GUATEMALA AND DOMINICAN REPUBLIC) ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 16 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

TABLE 17 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 18 COSTA RICA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 19 COSTA RICA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 20 COSTA RICA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 21 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 22 COSTA RICA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 23 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 24 COSTA RICA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 25 COSTA RICA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 26 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 27 COSTA RICA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 28 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 29 COSTA RICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 30 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

TABLE 31 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 32 PANAMA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 33 PANAMA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 34 PANAMA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 35 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 36 PANAMA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 37 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 38 PANAMA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 39 PANAMA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 40 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 41 PANAMA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 42 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 43 PANAMA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 44 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

TABLE 45 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 46 DOMINICAN REPUBLIC CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 47 DOMINICAN REPUBLIC TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 48 DOMINICAN REPUBLIC IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 49 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 50 DOMINICAN REPUBLIC BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 51 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 52 DOMINICAN REPUBLIC PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 53 DOMINICAN REPUBLIC ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 54 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 55 DOMINICAN REPUBLIC ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 56 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 57 DOMINICAN REPUBLIC ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 58 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

TABLE 59 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 60 GUATEMALA CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 61 GUATEMALA TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 62 GUATEMALA IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)

TABLE 63 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 64 GUATEMALA BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 65 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 66 GUATEMALA PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 67 GUATEMALA ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 68 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 69 GUATEMALA ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)

TABLE 70 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 71 GUATEMALA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 72 REST OF CENTRAL AMERICA ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Growth rate of the Central America Acute Myeloid Leukemia Drugs Market will grow at a CAGR of 5.5% during the forecast by 2029.
The major players operating in the Central America Acute Myeloid Leukemia Drugs Market are Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF Merck & Co., Inc.) (U.S.), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) (U.S.), AstraZeneca (U.K.), Viatris Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Fresenius Kabi AG (Germany), Teva Pharmaceutical Industries Ltd. (Israel) and Sun Pharmaceutical Industries Ltd. (India).
The major countries covered in the Central America Acute Myeloid Leukemia Drugs Market are Costa Rica, Panama, Dominican Republic, Guatemala, and Rest of Central America.